menu

CME: Immunotherapeutic Strategies for Advanced Renal Cell Carcinoma

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Immunotherapeutic Strategies for Advanced Renal Cell Carcinoma

Program Information
Recommended
Immunotherapeutic Strategies for Advanced Renal Cell Carcinoma
RestartResume
Explore recent advances and research for immunotherapeutic agents and combination strategies for the treatment of advanced renal cell carcinoma.

Available credits: 0.50

Time to complete: 30 Minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    There are several targeted agents that have been approved by the Food & Drug Administration (FDA) for the treatment of renal cell carcinoma (RCC). Although targeted therapies have improved patient outcomes, they do not achieve a durable complete response. Now, immune checkpoint inhibitors are gaining FDA approvals in RCC, with additional immunotherapeutic agents being studied in RCC, including combination strategies with targeted therapy and other immunotherapies.

    Clinical decision-making concerning sequencing of therapies for patients with RCC has become much more complex in the era of ever-increasing treatment options and advances in clinical trial research. Translating the most effective strategies for optimizing patient outcomes across multiple lines of therapy is becoming increasingly challenging for clinicians given the vast amount of new information. The emergence of immunotherapeutic and targeted compounds has raised many questions about how to optimize patient outcomes by the effective selection, timing, combination, and optimal sequencing of these agents.

    This activity will review clinical advances and emerging research for immunotherapeutic agents and combination strategies for the treatment of advanced renal cell carcinoma, including FDA-approved immunotherapies, guideline recommendations, recent clinical trial data on immunotherapy combination strategies, and adverse event management.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Discuss current and emerging immunotherapies and immunotherapy combinations for the treatment of renal cell carcinoma, including rationale, clinical data, and guideline recommendations
    • Develop strategies for selecting and sequencing immunotherapy and immunotherapy combinations for the treatment of patients with advanced renal cell carcinoma
    • Evaluate and plan approaches for detecting and managing immune-related adverse events of therapies associated with the treatment of advanced renal cell carcinoma
  • Target Audience

    This activity is intended for medical oncologists, urologists, surgeons, health system pharmacists, physician assistants, oncology nurses, and other healthcare professionals involved in the treatment of patients with advanced renal cell carcinoma.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity. Brian I. Rini, MD, reported a financial interest/relationship or affiliation in the form of Consultant, Pfizer, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Roche, AVEO Pharmaceuticals, Inc.; Research grant, Pfizer, Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck & Co., Inc., Peloton, Roche.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: The following AXIS planners and managers, Jocelyn Timko, BS;  Marilyn Haas, PhD, RN, CNS, ANP-BC; and Michael Brandt, PharmD, FASHP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Linda Gracie-King, MS (spouse) reports a financial interest / relationship or affiliation in the form of Common stock: Exelixis.

  • Continuing Medical Education

    Accreditation Statement

     In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 7/18/2020 PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hour of continuing pharmacy education credit JA4008106-0000-19-032-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Provider

    Provided by 

  • Disclosure of Unlabeled Use

    This activity is supported by an educational grant from Merck & Co, Inc.

  • Disclaimer

    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Method of Participation and Request for Credit

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 10/20/19

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.